Osteoarthritis in dogs: do intra-articular hyaluronan injections versus saline improve lameness and joint function? — POSSIBLE

In dogs with osteoarthritis, do intra-articular hyaluronan injections vs saline improve lameness and joint function?

Shelf #666 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: In naturally occurring canine osteoarthritis, the one randomised, double-blinded, saline-controlled trial carded here favours a hyaluronan product: in Alves 2021 (PMID: 33542412), 100 osteoarthritic hip joints were randomly assigned to saline control or one of four active intra-articular treatments, and the hylan G-F 20 group took longer to return to baseline values and scores than the saline group, with 57–81% improvements in functional evaluation and impairments due to osteoarthritis reported for the hylan and platelet-concentrate groups. A second, small trial in 16 dogs with hip-dysplasia osteoarthritis (Carapeba 2016, PMID: 27847523) also favoured intra-articular hyaluronic acid over an intra-articular saline control on pain-inventory and veterinarian scores at later time points — but that control group simultaneously received carprofen and a nutraceutical, so it is not a clean saline comparison. Against this, the largest saline-controlled function study, in an induced post-traumatic model (Smith 2005, PMID: 15693095; 30 dogs after anterior cruciate ligament transection), found hyaluronan made no difference to vertical ground reaction force or to osteoarthritis progression. Design class (a): randomisation and blinding are established by the Alves record's own wording ('a prospective, longitudinal, double-blinded, negative controlled study'; joints 'randomly assigned'; publication type Randomized Controlled Trial, Veterinary) and that record answers the shelf's own comparison (a hyaluronan product versus saline) in the shelf's own population (dogs with naturally occurring osteoarthritis). The stamp is POSSIBLE, not higher, because the naturally occurring evidence is one multi-arm trial whose abstract reports percentage improvements without absolute score values, plus one small confounded trial, while induced-model saline-controlled studies disagree with each other (two small studies positive on short-term lameness/range-of-motion outcomes; the 30-dog force-plate study null, Brandt 2004 also null on the same force-plate outcome, and the remaining pathology-focused induced-model studies mixed (Marshall 2000 positive on joint-structure outcomes at 2 months; Smith et al., PMID: 9627007, null on pathology)). Drafted Nov 10, 2026 (VetMed build, topic #666); all figures from the abstracts fetched and verified at drafting.

Alves 2021: in a randomised double-blinded trial of 100 osteoarthritic hip joints, hylan G-F 20 joints took longer to return to baseline than saline-control joints, with 57–81% improvements in functional evaluation reported for the hylan and platelet-concentrate groups

Randomized Controlled Trial, Veterinary (publication type); record's own wording: 'a prospective, longitudinal, double-blinded, negative controlled study'

Who: Dogs: 100 hip (pelvic limb) joints with naturally occurring osteoarthritis (mild n = 70, moderate n = 20, severe n = 10; patients mean age 6.5 ± 2.4 years, body weight 26.7 ± 5.2 kg) in a prospective clinical study. Joints were randomly assigned to five groups of 20 joints: saline control, triamcinolone hexacetonide, platelet concentrate, stanozolol, or hylan G-F 20 (a hyaluronan derivative), given as a single intra-articular injection. Evaluations on days 0, 8, 15, 30, 60, 90, 120, 150 and 180 consisted of weight-distribution analysis and four clinical metrology instruments.

Result: All treatment groups produced longer periods with better results in the various evaluations compared with the saline control group. Joints in the hylan G-F 20 and platelet-concentrate groups took longer to return to baseline values and scores. The platelet-concentrate and hylan groups experienced 57–81% improvements in functional evaluation and impairments due to osteoarthritis; the largest impact on pain interference was in the triamcinolone group (a 95% improvement over control). The authors conclude these intra-articular approaches relieved osteoarthritis clinical signs, varying in intensity and duration.

Watch out: The unit randomised and analysed is the joint (100 hip joints in five groups of 20), not the dog, and the abstract reports percentage improvements and time-to-return-to-baseline without absolute pain or function score values, so the size of the hylan effect cannot be read precisely. The tested product is hylan G-F 20, a cross-linked hyaluronan derivative — the result does not automatically extend to plain sodium hyaluronate preparations or other molecular weights — and four active arms were compared in the same trial, so this card uses only its saline-controlled hylan comparison.

Alves JC, Santos A, Jorge P, Lavrador C, Carreira LM. Sci Rep. 2021;11(1):3118. PMID: 33542412. Registry ID: none in the record. MeSH: Animals · Dogs · Female · Male · Anti-Inflammatory Agents*/therapeutic use · Blood Platelets/chemistry · Dog Diseases*/mortality, pathology, physiopathology, therapy · Forelimb · Hindlimb · Hyaluronic Acid*/analogs & derivatives, therapeutic use · Osteoarthritis*/mortality, pathology, therapy, veterinary · Pain*/drug therapy, mortality, pathology, veterinary · Pain Management · Proportional Hazards Models · Prospective Studies · Severity of Illness Index · Stanozolol*/therapeutic use · Triamcinolone Acetonide*/analogs & derivatives, therapeutic use · Working Dogs

Carapeba 2016: intra-articular hyaluronic acid beat a saline-plus-systemic-therapy control on pain scores in 16 dogs with hip-dysplasia osteoarthritis — lower CBPI scores from day 15 to 90 and lower veterinarian scores from day 60 to 90

Comparative clinical study (Journal Article); the record does not state randomisation or blinding

Who: Dogs: 16 dogs with osteoarthritis induced by hip dysplasia, distributed into two groups: a hyaluronic acid group receiving an intra-articular injection of hyaluronic acid (5–10 mg), and a control group receiving an intra-articular injection of saline solution (0.5–1.0 mL) combined with traditional conservative treatment — an oral nutraceutical (750–1000 mg every 12 h for 90 days) and carprofen (2.2 mg/kg every 12 h for 15 days). Dogs were assessed by a veterinarian on five occasions and owners completed the Helsinki Chronic Pain Index (HCPI) and Canine Brief Pain Inventory (CBPI) at the same times, over 90 days.

Result: Compared with baseline, lower scores were observed in both groups over the 90 days in the veterinarian evaluation, HCPI and CBPI (P < 0.001). The hyaluronic acid group exhibited lower scores from 15 to 90 days in the CBPI and from 60 to 90 days in the veterinarian evaluation, compared with the control group. The authors conclude both treatments reduced the clinical signs associated with hip osteoarthritis, with more significant results achieved with intra-articular hyaluronic acid injection.

Watch out: This is not a pure hyaluronan-versus-saline test: the saline group also received carprofen for 15 days and a nutraceutical for 90 days while the hyaluronic acid group's systemic co-treatment is not described, so group differences mix the injection with unequal systemic therapy. Only 16 dogs were studied (the abstract does not give the per-group numbers), allocation and blinding are not stated in the record, and the record carries no MeSH terms.

Carapeba GO, Cavaleti P, Nicácio GM, Brinholi RB, Giuffrida R, Cassu RN. Evid Based Complement Alternat Med. 2016;2016:2076921. PMID: 27847523. Registry ID: none in the record. MeSH: none in the record

Smith 2005: in 30 dogs with cruciate-transection-induced osteoarthritis, intra-articular hyaluronan had no effect on limb loading (the treatment made no difference) — peak vertical ground reaction force fell by ~60% after transection and recovered to ~75% of baseline regardless of treatment, with no significant difference in chondropathy or histology scores

Experimental induced-osteoarthritis model study (Journal Article); the record does not establish randomisation or blinding

Who: Dogs: 30 adult mixed-breed dogs in an experimental model — osteoarthritis induced by anterior cruciate ligament transection of the knee. Dogs were divided into 3 groups receiving 5 weekly intra-articular injections into the unstable knee during weeks 1–5 and 13–17: a prophylactic group (hyaluronan in the first series, saline in the second), a therapeutic group (saline first, hyaluronan second) and a control group (saline in both series). Joint damage was assessed by arthroscopy at 12 weeks and gross, histologic and biochemical examination at 32 weeks; limb loading was measured by force-plate analysis (peak vertical ground reaction force, VGRF).

Result: Mean arthroscopic chondropathy scores at 12 weeks were 2.5 ± 1.3 (controls), 2.5 ± 2.5 (therapeutic) and 2.1 ± 1.3 (prophylactic) on a 0–65 scale; gross chondropathy scores at 32 weeks were 14.0 ± 5.2, 17.6 ± 6.8 and 13.3 ± 5.0 respectively, with no significant differences among the means of the gross scores, the histologic scores, or the biochemical composition of articular cartilage. Peak VGRF in the unstable limb fell by ~60% after transection and rose slowly to ~75% of baseline over 32 weeks; hyaluronan injection had no effect on the VGRF or on the pathologic changes of osteoarthritis (the treatment made no difference).

Watch out: This is a surgically induced, post-traumatic osteoarthritis model in purpose-bred experimental dogs, not naturally occurring clinical osteoarthritis, and the hyaluronan was given on prophylactic or early-therapeutic schedules beginning 1–13 weeks after ligament transection — a different clinical situation from injecting a chronically osteoarthritic pet dog's joint. Its null function result therefore tempers, but does not cancel, the positive naturally occurring trials; equally, those trials do not cancel this null.

Smith G, Myers SL, Brandt KD, Mickler EA, Albrecht ME. J Rheumatol. 2005;32(2):325-34. PMID: 15693095. Registry ID: none in the record. MeSH: Adjuvants, Immunologic/administration & dosage, pharmacology, therapeutic use* · Animals · Anterior Cruciate Ligament/surgery · Anterior Cruciate Ligament Injuries* · Arthroscopy · Biomechanical Phenomena · Cartilage, Articular/drug effects, metabolism, pathology · Disease Models, Animal · Disease Progression · Dogs · Hyaluronic Acid/administration & dosage, pharmacology, therapeutic use* · Injections, Intra-Articular · Joint Instability/drug therapy*, pathology, physiopathology · Osteoarthritis, Knee/drug therapy*, physiopathology · Stifle/drug effects, pathology

Synthesis: saline-controlled evidence favours hyaluronan for lameness/function in naturally occurring canine osteoarthritis in one blinded randomised trial, but the largest induced-model function study is null — POSSIBLE

Synthesis

Who: Synthesis of the three cards above: Alves 2021 (100 osteoarthritic hip joints, randomised, double-blinded, hylan G-F 20 versus saline), Carapeba 2016 (16 dogs with hip-dysplasia osteoarthritis, hyaluronic acid versus saline injection plus carprofen/nutraceutical) and Smith 2005 (30 dogs, cruciate-transection-induced osteoarthritis, hyaluronan versus saline, force-plate function outcome).

Result: (1) Naturally occurring osteoarthritis: hylan G-F 20 joints took longer to return to baseline than saline controls, with 57–81% improvements in functional evaluation reported for the hylan group (Alves 2021); hyaluronic acid also scored better than a saline-plus-systemic-therapy control on owner pain inventory from day 15 and veterinarian evaluation from day 60 (Carapeba 2016). (2) Induced post-traumatic model: hyaluronan had no effect on vertical ground reaction force or osteoarthritis progression in 30 dogs (Smith 2005 — the treatment made no difference). (3) No carded trial reports a mortality or other hard-outcome effect; all outcomes are pain, lameness, function scores or joint pathology.

Watch out: One-home check at drafting: none of PMIDs 33542412, 27847523 or 15693095 appears in any other pack on disk. Records deliberately not carded as claim-carriers: two small placebo/saline-controlled studies in surgically induced osteoarthritis models reported short-term benefit — Pashuck 2016 (PMID: 26867692; 25 purpose-bred dogs after meniscal release; hyaluronic acid groups significantly better than saline groups at 4, 8 and 12 weeks on at least one outcome measure) and Lee 2019 (PMID: 31533754; 12 beagles after cruciate resection; 4 per group; hyaluronic acid better than saline on range of motion and lameness at 2, 4 and 12 weeks) — both are induced-model studies whose populations home with the experimental-model question rather than clinical osteoarthritis, and they are noted here because they conflict with Smith 2005's null within the same model class. Induced-model studies focused mainly on joint structure are likewise not carded: Brandt 2004 (PMID: 15299280) measured cartilage and joint-structure outcomes AND the same vertical-ground-reaction-force outcome as Smith 2005, and was null on all of them; Marshall 2000 (PMID: 10937628) found significantly less severe osteoarthritis changes in knees treated with hylan G-F 20 two months after surgery than in contralateral untreated knees — a positive pathology result; Smith et al. (PMID: 9627007) found pathology severity comparable with controls — null. Post-surgical hyaluronan after patellar-luxation surgery (PMID: 23814475) answers a different (postoperative) question.

Synthesis of Alves JC et al. PMID: 33542412; Carapeba GO et al. PMID: 27847523; Smith G et al. PMID: 15693095. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.